WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising a micromolecule PI4KIIIα inhibitor and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises a lipid.

~~2. The pharmaceutical composition according to claim 1, wherein the micromolecule PI4KIIIα inhibitor is PAO and a derivative of PAO.~~

~~3~~2. The pharmaceutical composition according to claim 1, wherein the micromolecule PI4KIIIα inhibitor has a structure of formula (I) or a pharmaceutically acceptable salt thereof,



formula (I)

wherein R_1 is each independently selected from H, halogen, nitro, cyano, hydroxyl, amino, carbamoyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, -As(O), -NH-(C_{1-6} alkyl), N,N-(C_{1-6} alkyl)$_2$, -NH-C(O)-R_2, -NH-S(O)$_2$-R_3, -C(O)OR_4 or heterocyclyl, wherein n is an integer of 0-5, R_2 and R_3 are each independently selected from H, amino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, -NH-(C_{1-6} alkyl), N,N-(C_{1-6} alkyl)$_2$, -C(O)OR_4, C_{3-6} cycloalkyl, 6-12 membered aryl or 3-6 membered heterocyclyl, which are optionally substituted by halogen, nitro, cyano, hydroxyl, amino, carbamoyl, aryl, C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, 3-6 membered heterocyclyl, C_{3-6} cycloalkyl or Bn-O-, and R_4 is C_{1-6} alkyl.

~~4. The pharmaceutical composition according to claim 3, wherein R_1 is each independently selected from H, halogen, nitro, cyano, hydroxyl, amino, carbamoyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, -As(O), -NH-(C_{1-6} alkyl), N,N-(C_{1-6} alkyl)$_2$ or -C(O)OR_4, wherein n is an integer of 0-2, and R_4 is C_{1-6} alkyl.~~

~~5~~3. The pharmaceutical composition according to claim ~~3~~2, wherein R_1 is each independently selected from H, halogen, nitro, cyano, hydroxyl, amino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl or -As(O), wherein n is an integer of 0-2.

~~6. The pharmaceutical composition according to claim 3, wherein R_1 is each independently selected from H, halogen, amino or C_{1-6} alkoxy, wherein n is 1.~~

~~7. The pharmaceutical composition according to claim 6, wherein R_1 is located at an ortho position or a para position of the -As(O) group.~~

~~8~~4. The pharmaceutical composition according to claim ~~3~~2, wherein R_1 is H.

~~9~~5. The pharmaceutical composition according to claim 1, wherein the micromolecule PI4KIIIα inhibitor is at an amount of 0.01-20 mg/g, 0.05-20 mg/g, 0.1-20 mg/g, 0.2-20 mg/g, 0.5-20 mg/g, 0.8-20 mg/g, 1-20 mg/g, 1-18 mg/g, 1-16 mg/g, 1-14 mg/g, 1-12 mg/g, 1-10 mg/g, 2-10 mg/g, 2-8 mg/g, 2-6 mg/g, 3-6 mg/g, 0.2-15 mg/g, 0.2-12 mg/g, 0.2-10 mg/g, 0.2-8 mg/g, 0.2-6 mg/g, 0.2-4 mg/g, 0.2-2 mg/g, 0.2-1 mg/g or 0.2-0.8 mg/g in the pharmaceutical composition.

~~10~~6. The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable carrier comprises at least about 50% (w/w), at least about 60% (w/w), at least about 70% (w/w), at least about 80% (w/w), at least about 85% (w/w), at least about 90% (w/w), at least about 95% (w/w), at least about 97% (w/w), at least about 98% (w/w), at least about 99% (w/w) or 100% (w/w) of the lipid.

~~11. The pharmaceutical composition according to any one of the preceding claims, wherein the lipid comprises a lipid with a melting point of -20-80°C, -20-10°C or -20-0°C.~~

~~12. The pharmaceutical composition according to any one of the preceding claims, wherein the lipid has a degree of unsaturation of 0-5, 0-4, 0-3, 0-2, 0-1 or 0.~~

~~13. The pharmaceutical composition according to any one of the preceding claims, wherein the lipid comprises a lipid which has a fatty acid carbon chain at a length in a range of 4-24, 4-22, 4-20, 6-20, 6-16, 6-14, 6-13, 6-12, 8-13, 8-12 or 8-10 carbon atoms.~~

~~14. The pharmaceutical composition according to any one of the preceding claims, wherein the lipid comprises a lipid which has a fatty acid chain at a length of 8 and 10, and optionally further comprises a lipid which has the fatty acid carbon chain at a length of 12-22.~~

~~15. The pharmaceutical composition according to any one of the preceding claims, wherein the fatty acid chain in the lipid is a long-chain fatty acid, a medium-chain fatty acid or a short-chain fatty acid.~~

~~16. The composition according to claim 1, wherein the lipid is vegetable oil.~~

~~17. The pharmaceutical composition according to claim 16, wherein the vegetable oil is olive oil, tea oil, rapeseed oil, peanut oil, soybean oil, corn oil, safflower oil, groundnut oil, sunflower seed oil, canola oil, walnut oil, almond oil, avocado oil, castor oil, coconut oil, cottonseed oil, rice bran oil, sesame oil, refined palm oil or a mixture thereof.~~

~~18. The pharmaceutical composition according to any one of the preceding claims, wherein the lipid is a fatty acid, a fatty acid ester, a fatty alcohol, a lipoid, a paraffin or a mixture thereof.~~

~~19. The pharmaceutical composition according to claim 18, wherein the lipoid is a phospholipid, a sucrose ester, a steroid, a fat-soluble vitamin or a mixture thereof.~~

~~20~~7. The pharmaceutical composition according to claim 1~~8~~, wherein the lipid is a fatty acid, a fatty acid ester, a fatty alcohol, a lipoid, a paraffin or a mixture thereof, and wherein the fatty acid ester is a glyceride, an ethylene glycol ester, a propylene glycol ester or a mixture thereof.

~~21~~8. The pharmaceutical composition according to claim 1~~8~~, wherein the lipid is a fatty acid, a fatty acid ester, a fatty alcohol, a lipoid, a paraffin or a mixture thereof, and wherein the fatty acid ester is a monoester, a diester, a triester or a mixture thereof.

~~22~~9. The pharmaceutical composition according to claim 1~~8~~, wherein the lipid is a fatty acid, a fatty acid ester, a fatty alcohol, a lipoid, a paraffin or a mixture thereof, and wherein the fatty acid ester comprises glycerides of octanoic acid and/or decanoic acid.

~~23~~10. The pharmaceutical composition according to claim 1~~8~~, wherein the lipid is a fatty acid, a fatty acid ester, a fatty alcohol, a lipoid, a paraffin or a mixture thereof, and wherein the fatty acid ester comprises a medium-chain triglyceride.

~~24. The pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutically acceptable carrier further comprises an antioxidant.~~

~~25. The pharmaceutical composition according to claim 24, wherein the antioxidant is at an amount of 0.001% 5% (wt), 0.005% 5% (wt), 0.01% 5% (wt), 0.05% 5% (wt), 0.1% 5% (wt), 0.1% 3% (wt), 0.1% 2% (wt), 0.1% 1% (wt), 0.1% 0.8% (wt), 0.1% 0.5% (wt), 0.1% 0.3% (wt), 0.3% 2% (wt), 0.5% 2% (wt), 0.8% 2% (wt) or 1% 2% (wt) based on the weight~~

~~of the pharmaceutical composition.~~

~~26. The pharmaceutical composition according to claim 24, wherein the antioxidant is sulfite, bisulfite, pyrosulfite, dithiocarbamate, ascorbic acid, ascorbyl palmitate, hydrocoumarin, vitamin E, ethanolamine, propyl gallate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), nordihydroguaiaretic acid or glutathione.~~

~~27. The pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutically acceptable carrier further comprises a viscosity modifier, a pH regulator or a flavoring agent.~~

~~28. The pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutically acceptable carrier further comprises ethanol.~~

~~29. The pharmaceutical composition according to claim 28, wherein the ethanol is at an amount of 10% 0.1% (v/v).~~

~~30. The pharmaceutical composition according to claim 28, wherein the ethanol is at an amount of 8% 0.1% (v/v), 7% 0.1% (v/v), 6% 0.1% (v/v), 5% 0.1% (v/v), 4% 0.1% (v/v), 3% 0.1% (v/v), 2% 0.1% (v/v), 1.5% 0.1% (v/v), 1.2% 0.1% (v/v), 8% 0.3%(v/v), 8% 0.5%(v/v), 8% 0.7%(v/v), 8% 0.9% (v/v), 8% 1% (v/v), 6% 0.3% (v/v), 5% 0.5% (v/v), 4% 0.8% (v/v), 3% 0.9% (v/v) or 2% 1% (v/v).~~

~~31. The pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutical composition is used for oral, subcutaneous, intramuscular or intravenous administration.~~

~~32. The pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutical composition is tablets, capsules, suspensions, emulsions, solutions, semisolid preparations, patches or microneedles.~~

~~33~~11. The pharmaceutical composition according to claim 1, wherein the micromolecule PI4KIIIα inhibitor is phenylarsine oxide, the phenylarsine oxide is at an amount of 0.25-20 mg/g in the pharmaceutical composition, and the pharmaceutically acceptable carrier is consisting of a medium-chain triglyceride, consisting of a medium-chain triglyceride and a long-chain triglyceride, or consisting of a medium-chain triglyceride and ethanol.

~~34. A method for preparing the pharmaceutical composition according to any one of claims~~

~~1-33, wherein the method comprises: mixing the micromolecule PI4KIIIα inhibitor and the pharmaceutically acceptable carrier to obtain a mixture.~~

~~35. The method according to claim 34, wherein the method comprises: mixing the micromolecule PI4KIIIα inhibitor and the pharmaceutically acceptable carrier through a mechanical force.~~

~~36. The method according to claim 35, wherein the mechanical force is stirring, dispersing, shaking or ultrasonic treatment.~~

~~37. The method according to claim 34, wherein the method comprises: mixing the micromolecule PI4KIIIα inhibitor and the pharmaceutically acceptable carrier after melting the pharmaceutically acceptable carrier by heating.~~

~~38. The method according to claim 37, further comprising: filtering the mixture.~~

~~39~~12. Use of the pharmaceutical composition according to any one of claims 1-11 in the manufacture of a medicament ~~A method~~ for treating a PI4KIIIα-related disease in a subject~~, wherein the method comprises administrating the pharmaceutical composition according to any one of claims 1-33 to a subject in need thereof~~.

~~40~~13. The ~~method~~ use according to claim ~~39~~12, wherein the PI4KIIIα-related disease is Alzheimer's disease.

~~41~~14. The ~~method~~ use according to claim ~~39~~12, wherein the subject is an animal such as a pig, a dog, a monkey, a cat, a mouse, or a rat, or a human.

~~42. Use of the pharmaceutical composition according to any one of claims 1-33 in the manufacture of a medicament for treating a PI4KIIIα-related disease in a subject.~~

~~43~~15. The pharmaceutical composition according to any one of claims 1-~~33~~11 for use in treating a PI4KIIIα-related disease in a subject.